P694: Genetic predisposition and thiopurine-induced pancreatitis in inflammatory bowel disease patients
ECCO '19 Copenhagen
2019
P695: Feasibility and safety of strictureplasties performed by laparoscopic approach for complicated Crohn’s disease: A prospective observational cohort study
ECCO '19 Copenhagen
2019
P696: Long-term prognosis and predictive factors for surgical treatment of intestinal lesions in patients with Behcet’s disease
ECCO '19 Copenhagen
2019
P697: Pneumocystis jirovecii pneumonia in IBD patients treated with immunomodulator(s)
ECCO '19 Copenhagen
2019
P698: Persistence, clinical effectiveness and safety of vedolizumab in the post-marketing real clinical practice in Italy: a double-centre, 2-year experience in Crohn’s disease and ulcerative colitis patients
ECCO '19 Copenhagen
2019
P699: Faecal microbiota transplantation as treatment for recurrent clostridium difficile infections: a single-centre experience
ECCO '19 Copenhagen
2019
P700: The efficacy of colesevelam to treat bile acid malabsorption in Crohn's disease: data from TOPPIC trial
ECCO '19 Copenhagen
2019
P701: The comparative safety of different intravenous iron preparations in inflammatory bowel disease: a systematic review and network meta-analysis
ECCO '19 Copenhagen
2019
P702: Off-label drug use in patients with inflammatory bowel disease: a national survey among tertiary care centres
ECCO '19 Copenhagen
2019
P703: The real-world long-term effectiveness of vedolizumab in inflammatory bowel diseases: a single-centre observational study
ECCO '19 Copenhagen
2019
P704: Association between trough levels of vedolizumab and therapy outcome in a cohort of patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P705: Incidence and risk factors of micronutrient deficiency in the patients with inflammatory bowel disease in Korea: folate, vitamin B12, 25-OH-vitamin D, ferritin
ECCO '19 Copenhagen
2019
P706: Patient knowledge towards biological treatment in inflammatory bowel diseases: a cross-sectional survey
ECCO '19 Copenhagen
2019
P707: 38 Weeks treatment of UC patients with different daily doses of mesalazine
ECCO '19 Copenhagen
2019
P708: Prospective study to predict psychological morbidity in young people with inflammatory bowel disease using novel risk assessment tool
ECCO '19 Copenhagen
2019
P709: Early measurement of serum cytokines as predictor of clinical and endoscopic outcome to vedolizumab in patients with ulcerative colitis
ECCO '19 Copenhagen
2019
P710: The use of first-line biologics in patients with Crohn’s disease in Norway from 2011 to 2016
ECCO '19 Copenhagen
2019
P711: The real-life experience of vedolizumab therapy in the OBSERV-IBD cohort: a 3-year prospective observational multi-centre cohort study
ECCO '19 Copenhagen
2019